Q9T.F ME Therapeutics Holdings Inc.
- Market cap
- EUR 60.1M
- P/E
- -
- P/B
- 147.62x
- ROE
- -215.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is Q9T.F undervalued?
Graham numberThe Graham number of ME Therapeutics Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ME Therapeutics Holdings Inc. fundamental analysis
No fundamental analysis for ME Therapeutics Holdings Inc. yet.
ME Therapeutics Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and my…
Full company profileME Therapeutics Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ME Therapeutics Holdings Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -295K | -977K | -1.33M | -1.22M | -1.40M |
| EBITDA | -3.29M | -6.51M | -1.29M | -1.10M | -1.27M |
| Net Income | -3.30M | -6.52M | -1.29M | -1.19M | -1.39M |
| EPS | -0.14 | -0.28 | -0.05 | -0.04 | -0.05 |
| Balance Sheet | |||||
| Total Assets | 398K | 672K | 1.54M | 1.76M | 796K |
| Total Liabilities | 35.4K | 148K | 62.9K | 256K | 151K |
| Shareholders' Equity | 363K | 523K | 1.48M | 1.50M | 645K |
| Cash & Short-term Investments | 398K | 647K | 1.50M | 1.35M | 479K |
| Cash Flow | |||||
| Operating Cash Flow | - | -303K | -658K | -862K | -1.29M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 216K | 41.6K |
| Free Cash Flow | - | -303K | -658K | -1.08M | -1.33M |
| Ratios | |||||
| ROE | -911.6% | -1,245.8% | -87.7% | -79.4% | -215.4% |
| ROA | -830.5% | -970.5% | -84.1% | -67.8% | -174.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ME Therapeutics Holdings Inc. dividends
ME Therapeutics Holdings Inc. has not paid dividends in the last 4 fiscal years.
Who owns ME Therapeutics Holdings Inc.
- Insiders 54.71%
- Institutions 0.00%
- Public & others 45.29%
- Shares outstanding 30.0M
- Free float 13.1M
ME Therapeutics Holdings Inc. company profile
- Company name
- ME Therapeutics Holdings Inc.
- Ticker
- Q9T.F
- ISIN
- CA5527671054
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- August
- Address
- 177 Robson Street, Vancouver, BC, Canada, V6B 0N3
- Phone
- 236 516 7714
- Website
- metherapeutics.com
About ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
ME Therapeutics Holdings Inc. management
4- Dr. Salim Zulifkar Dhanji Ph.D.Founder, CEO & Director
- Mr. Quinn Martin C.A., CPAChief Financial Officer · born 1982
- Mr. Karim F. Lalji M.S., SMChief Business Officer
- Mr. Jamil KassamCorporate Secretary